Orphazyme A/S reports solid financial results, strategic changes, acquisitions, and plans for capital expansion

From GlobeNewswire: 2024-08-20 02:45:00

Orphazyme A/S reported financial results for the first half of 2024, achieving an EBIT of DKK 1.7 million. The company’s equity as of June 2024 is DKK 16.1 million. Legal cases in the US have been concluded, and disputes with Zevra have been resolved.

The company entered a strategic partnership by acquiring 10% ownership of Combigene AB, a Swedish biotech company. Looking to make further investments to increase shareholder value, the company is actively seeking new opportunities.

Orphazyme A/S is undergoing an identity change to broaden its focus areas. The proposed change includes a new mission statement and a name that better reflects the company’s future strategic direction. Shareholder approval will be sought at an extraordinary general meeting.

To support its new strategy, Orphazyme A/S plans to raise capital through directed share issuances. An increase in capital is expected after Nasdaq approval. All shareholders are welcome to participate in the upcoming and future capital expansions.

Maintaining its guidance for 2024, Orphazyme A/S expects an operating result between DKK -1 to +1 million for the year. Shareholders seeking more information can contact Michael Hove, Chairman of the Board, at +45 28126609.



Read more at GlobeNewswire:: Delårsrapport 2024 – Fortsat eksekvering på strategi